104
Participants
Start Date
October 31, 2025
Primary Completion Date
August 31, 2029
Study Completion Date
August 31, 2029
EXPAREL
EXPAREL (bupivacaine liposome injectable suspension) is formulated as a sterile, non-pyrogenic, white to off-white, preservative-free homogenous suspension of bupivacaine encapsulated into multivesicular liposomes (pMVL drug delivery system). For this study, EXPAREL will be provided in 20 mL (266 mg) EXPAREL single-use, clear glass vials.
0.25% bupivacaine (HCl): 50 ml
The reference product is 50 mL (125 mg) 0.25% bupivacaine HCl administered via a combined sciatic (in the popliteal fossa) and saphenous nerve block (in the adductor canal)
0.25% bupivacaine (HCl): 30 ml
EXPAREL admixed with 30 mL (75 mg) 0.25% bupivacaine HCl
Emory University Orthopaedic Hospital Musculoskeletal Institute (MSK), Atlanta
Collaborators (1)
Pacira Pharmaceuticals, Inc
INDUSTRY
Emory University
OTHER